Monrovia, CA, April 14, 2007 --(PR.com
)-- At this year’s Protein Kinases in Drug Discovery conference organized by GTCbio, a special panel of researchers will assemble to discuss the challenges and progress associated with the inhibition of kinases in chronic and acute disorders.
The panel will review the advantages and disadvantages for treating different disorders and look into whether the inhibition of kinases is really a viable path towards treating these disorders. The clinical issues related to inhibition will also be covered by the panelists.
Among the panelists is Dr. Jessie English, Director of Kinase Center of Emphasis at Pfizer, Dr. Andrew West, Instructor at the Department of Neurology at Johns Hopkins University, Dr. Sridhar Rabindran, Associate Director of Oncology Research at Wyeth Research and Dr. Maria Webb, Vice President of Preclinical Research, Biological & Pharmacological Sciences at Pharmacopeia. Moderating the panel is Dr. Paul Jackson, Team Leader of CNS Research at Johnson & Johnson.
The 2nd Protein Kinases in Drug Discovery conference will take place on May 31 – June 1, 2007 at the Omni Parker House Hotel in Boston, Massachusetts. Additional topics to be covered include Technologies for Identifying Kinase Targets and Inhibitors, Kinase Targets and Inhibitors in Oncology, CNS, and Inflammatory Disorders.
Among the prestigious organization to present are Pfizer, Merck, Johnson & Johnson, Wyeth, GlaxoSmithKline, Eli Lilly, Bristol Myers Squibb, Genentech, AstraZeneca, Schering-Plough, Abbott Laboratories, Boehringer Ingelheim, Amgen, MIT, Johns Hopkins University, Harvard University, and the National Cancer Institute of the National Institutes of Health.
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://www.gtcbio.com/conference/conferenceDetails.aspx?id=93
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.